Biodyne Co., Ltd.
Financials
Valuation Metrics
Biodyne Co., Ltd.'s Market Cap is ₩2545B. At end of 2025 it was ₩4018B. Ranked #707 of 2,436 in KR market (top 29%), #298 of 1,649 on KOSDAQ (top 18%), #22 of 96 in Health Care Equipment & Services (top 23%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 254.48B KRW | KR#707/2,436 Sec#22/96 |
| Revenue | 6.98B KRW | KR#2,320/2,436 Sec#85/96 |
| Net Income | 1.44B KRW | KR#1,396/2,436 Sec#43/96 |
| Total Assets | 44.77B KRW | KR#2,232/2,436 Sec#77/96 |
| Net Assets | 44.30B KRW | KR#1,960/2,436 Sec#65/96 |
| Employees | 19 | KR#2,229/2,436 Sec#86/96 |
| Value | ||
| P/E | 176.49x | KR#1,466/2,436 Sec#48/96 |
| P/B | 5.74x | KR#2,266/2,436 Sec#86/96 |
| PEG | 1.95x | KR#796/2,436 Sec#32/96 |
| P/S | 36.47x | KR#2,357/2,436 Sec#91/96 |
| EV/EBITDA | 229.24x | KR#1,531/2,436 Sec#49/96 |
| FCF Yield | -1.02% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | 3.25% | KR#1,203/2,436 Sec#44/96 |
| ROA | 3.22% | KR#926/2,436 Sec#37/96 |
| Op. Margin | 15.14% | KR#276/2,436 Sec#23/96 |
| Revenue Growth | -5.40% | KR#1,713/2,436 Sec#69/96 |
| Earnings Growth | 90.39% | KR#442/2,436 Sec#18/96 |
| Financial Health | ||
| Debt Ratio | 101.06% | KR#327/2,436 Sec#13/96 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/96 |
| FCF | -2.60B KRW | KR#1,373/2,436 Sec#45/96 |
| Cash | 12.22B KRW | KR#1,552/2,436 Sec#54/96 |
| Current Ratio | 39.77x | KR#7/2,436 Sec#1/96 |
| Net Debt/EBITDA | -11.57x | KR#59/2,436 Sec#4/96 |
| Performance | ||
| 1Y Return | -40.38% | KR#1,844/2,436 Sec#65/96 |
| 1M Return | -9.81% | KR#1,746/2,436 Sec#69/96 |
| From 52W High | -49.29% | KR#1,155/2,436 Sec#44/96 |
| 1Y MDD | -54.02% | KR#1,111/2,436 Sec#41/96 |
| Trading | ||
| Volume | 26,045 shares | KR#1,736/2,436 Sec#72/96 |
| Foreign Own. | 4.48% | KR#847/2,436 Sec#30/96 |
| Per Share | ||
| EPS | 49 KRW | KR#1,449/2,436 Sec#47/96 |
| BPS | 1,503 KRW | KR#2,157/2,436 Sec#76/96 |
Company Info
Established in 2013, the company develops, manufactures, and sells liquid-based cytology equipment and cancer diagnostic reagent kits, completing a special listing on the KOSDAQ market in 2021. It exports its independently developed blowing technology-based LBC equipment, 'PATHPLORER', and reagent kits to 13 countries, securing patents in multiple nations. The company has an exclusive license agreement with Roche for slide smearing device development, planning to unveil 'VENTANA SP400' in Japan in 2025 and pursue global sales. Biodine is headquartered in Seongdong-gu, Seoul.